SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Walker, S E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walker, S E
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Reviews

Bromocriptine treatment of systemic lupus erythematosus

S E Walker

Department of Internal Medicine, The University of Missouri-Columbia, Columbia, Missouri, USA; Department of Internal Medicine, MA406G Health Sciences Center, One Hospital Drive, Columbia, MO 65212, USA sewk{at}tranquility.net;walkers@health.missouri.edu

Prolactin, a peptide hormone, acts as a cytokine. It has been hypothesized that bromocriptine, a dopamine analog that suppresses pituitary secretion of prolactin, suppresses circulating prolactin and, through this mechanism, has the potential to suppress autoimmune disease. This rationale has been applied to the treatment of systemic lupus erythematosus (SLE), a prototype autoimmune illness that occurs spontaneously in animal models such as the F1 hybrid NZB NZW mouse, and in humans. Treatment with bromocriptine was effective in treating some induced and spontaneous autoimmune disease in experimental models. Bromocriptine did slow the course of SLE in NZB NZW mice when treatment was started before the appearance of clinical disease. In addition, bromocriptine was effective in treating established disease in this model. In three separate clinical trials, bromocriptine showed evidence that it had a therapeutic effect in treating human lupus. Bromocriptine is currently considered an unproven therapy for SLE. Its use is entirely experimental. The fact that bromocriptine was effective in treating NZB-NZW mice, the beneficial therapeutic effects in human trials, and the low toxicity of the drug form a solid rationale for undertaking further therapeutic trials.

Key Words: systemic lupus erythematosus • bromocriptine • prolactin

Lupus, Vol. 10, No. 10, 762-768 (2001)
DOI: 10.1191/096120301717165010
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
J. Cohen-Solal, V Jeganathan, L Hill, D Kawabata, D Pinto-Rodriguez, C Grimaldi, and B Diamond
Hormonal regulation of B-cell function and systemic lupus erythematosus
Lupus, June 1, 2008; 17(6): 528 - 532.
[Abstract] [PDF]

Home page
 LupusHome page
D. J. Petro
Treatment of systemic lupus erythematosus with bromocriptine
Lupus, April 1, 2002; 11(4): 266 - 267.
[PDF]

Home page
 Recent Prog Horm ResHome page
L.-Y. Yu-Lee
Prolactin Modulation of Immune and Inflammatory Responses
Recent Prog. Horm. Res., January 1, 2002; 57(1): 435 - 455.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
L.-y. Yu-Lee
Stimulation of interferon regulatory factor-1 by prolactin
Lupus, October 1, 2001; 10(10): 691 - 699.
[Abstract] [PDF]


Advertisement